![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib (GvHD Hub) View |
![]() |
Implications for Treating Acute GVHD With Ruxolitinib (OncLive) View |
![]() |
Initial, Steroid-Refractory, and Novel Treatment Options for GVHD (Targeted Oncology) View |
![]() |
REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD (GvHD Hub) View |
![]() |
Case 2: Treating Steroid-Refractory Acute Graft-Versus-Host Disease (Targeted Oncology) View |
![]() |
Management of acute and chronic GvHD (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
Case 3: Treating Moderate Chronic Graft-Versus-Host Disease (Targeted Oncology) View |
![]() |
Completed Clinical Trials of JAK Inhibitors for Treatment of Acute GVHD: Itacitinib u0026 Ruxolitinib (MedEdOTG) View |
![]() |
Case 2: Treating Steroid-Refractory Acute GVHD (Targeted Oncology) View |
![]() |
Case 3: Supportive Care in Chronic GVHD (Targeted Oncology) View |